Table 3.

Odds Ratios (OR) with 95% Wald Confidence Intervals (CI) for adjusted logistic regression of failure to reach a viral load (VL) <400 copies/ml at six and twelve months of treatment in children initiating ritonavir-boosted lopinavir (LPV/r)- or efavirenz (EFV)-based antiretroviral treatment (ART)

	LPV/r-based N=4369				EFV-based N=5174
	Six Months	p	Twelve Months	p	Six Months	p	Twelve Months	p
Unadjusted OR (95% CI):
d4T-based vs. ABC-based	0.49 (0.40–0.60)	<0.0001	0.52 (0.39–0.69)	0.001	0.56 (0.43; 0.72)	<0.0001	0.55 (0.36–0.85)	0.013
Adjusted OR (95% CI):
d4T-based vs. ABC-based	0.57 (0.46–0.72)	<0.0001	0.69 (0.46–1.02)	0.061	0.46 (0.32–0.65)	<0.0001	0.56 (0.36–0.86)	0.012
Male	0.99 (0.86–1.15)	0.942	1.05 (0.85–1.29)	0.62	1.07 (0.90–1.27)	0.415	1.05 (0.83–1.33)	0.648
Age at Initiation*	0.70 (0.57–0.87)	0.002	0.86 (0.57–1.30)	0.411	0.99 (0.99–1.00)	0.001	1.00 (0.99–1.00)	0.631
Pre-Treatment Weight-for-Age Z-score	0.89 (0.83–0.96)	0.007	0.93 (0.89–0.98)	0.006	0.91 (0.85–0.98)	0.009	0.93 (0.86–1.01)	0.085
Pre-Treatment CD4%	0.98 (0.96–1.00)	0.043	0.98 (0.97–0.99)	0.003	0.98 (0.97–1.00)	0.032	0.98 (0.96–0.99)	0.002
Pre-Treatment VL < 100,000 copies/ml	0.65 (0.52–0.82)	<0.0001	0.69 (0.49–0.96)	0.032	0.72 (0.58–0.88)	0.002	0.79 (0.64–0.99)	0.04
Year of ART initiation	1.06 (1.01–1.12)	0.026	1.12 (1.04–1.20)	0.004	0.97 (0.92–1.03)	0.358	1.02 (0.95–1.10)	0.555

Adjusted for cohort (individual cohort results not shown). Odds Ratios < 1 indicate factors improving viral suppression rate at six months.

^*Age at initiation categorized as < six months (reference) and > six months of age for LPV/r group and as continuous variable (months) for EFV group.

Abbreviations: stavudine (d4T) and abacavir (ABC)